In-Vivo Models and Studies

LIDE’s CRO foundation is in traditional in-vivo studies, providing standard in-vivo efficacy platforms like CDX and PDX. Years of innovation and a penchant for using the latest technologies has resulted in novel LIDE offerings also.

Technology Purpose Why LIDE
PDX – Patient Derived Xenograft Gold standard for IND filing – 89% correlation with clinical response Over 1600 LIDE PDX models, many with rare gene alterations or drug resistance
MiniPDX®  Novel, more cost-effective alternative to PDX with faster turnaround time, but still well correlated with PDX results and clinical response LIDE has optimized its MiniPDX® technologies for years, with several supporting papers and currently running a RWE study in China
CDX – Cell-line Derived Xenograft Traditional pre-cursor to PDX – only 5% correlation with clinical response Over 50 LIDE CDX models,
CRC – Conditionally Reprogrammed Cells Novel alternative to commercialized cell lines to maintain heterogeneity, to increase correlation with clinical results LIDE has years of experience working with CRCs to expand cell cultures from patient tissue samples for in-vivo studies


LIDE’s Functional Diagnosis platform offers drug companies a more efficient pathway to successful clinical trials.

Learn more about Functional Diagnosis


LIDE’s IO platform leverages HuPBMC reconstituted or co-inoculated (with commercialized cell line or PDX cell suspension) models established from CDXs or PDXs.

Learn more about LIDE's IO platform

Fig. New, optimized R&D roadmap using LIDE Functional Diagnosis platform
Fig. New, optimized R&D roadmap using LIDE Functional Diagnosis platform